STOCK TITAN
  1. Home
  2. Sec-filings
  3. FDMT
  4. [Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity

Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

4D Molecular Therapeutics director and officer David Kirn reported an open-market sale of 114,746 shares of Common Stock at a weighted average price of $10.4653 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, meaning it was pre-scheduled rather than timed discretionarily. After this sale, Kirn directly holds 942,485 shares of the company’s stock.

Positive

  • None.

Negative

  • None.

Insights

Pre-planned insider sale reduces holdings but leaves a sizable remaining stake.

Director and officer David Kirn sold 114,746 shares of 4D Molecular Therapeutics common stock in an open-market transaction at a weighted average price of $10.4653 per share. This is a straightforward insider disposition rather than an option exercise or restructuring.

The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026, indicating the trades were pre-arranged. Kirn continues to hold 942,485 shares directly, so the transaction represents a partial reduction of his position rather than a full exit.

Insider Kirn David
Role See Remarks
Sold 114,746 shs ($1.20M)
Type Security Shares Price Value
Sale Common Stock 114,746 $10.4653 $1.20M
Holdings After Transaction: Common Stock — 942,485 shares (Direct)
Footnotes (2)
  1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
  2. F2. The transaction was executed in multiple trades in prices ranging from $10.00 to $10.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Shares sold 114,746 shares Open-market sale on June 22, 2026
Weighted average sale price $10.4653 per share Common Stock sale
Shares held after transaction 942,485 shares Direct holdings following sale
Net shares sold 114,746 shares Net buy/sell direction: net-sell
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported in Column 4 above reflects the weighted average sale price."
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did 4D Molecular Therapeutics (FDMT) report for David Kirn?
4D Molecular Therapeutics reported that director and officer David Kirn sold 114,746 shares of common stock in an open-market transaction. The weighted average sale price was $10.4653 per share, and the sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

How many FDMT shares does David Kirn hold after this Form 4 transaction?
After the reported sale, David Kirn directly holds 942,485 shares of 4D Molecular Therapeutics common stock. This figure reflects his position following the open-market disposition of 114,746 shares disclosed in the Form 4 insider trading report.

Was David Kirn’s sale of FDMT shares made under a Rule 10b5-1 plan?
Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by David Kirn on January 9, 2026. Such plans pre-schedule trades, reducing the significance of short-term timing decisions for interpreting insider sentiment.

What price did David Kirn receive for the FDMT shares he sold?
The Form 4 reports a weighted average sale price of $10.4653 per share for David Kirn’s 114,746 FDMT shares. Trades occurred in multiple transactions within a price range from $10.00 to $10.87 per share, as detailed in the filing’s footnotes.

How large was David Kirn’s FDMT share sale compared with his remaining holdings?
David Kirn sold 114,746 shares and retained 942,485 shares directly after the transaction. This means he continues to hold a substantial position in 4D Molecular Therapeutics, with the reported sale representing only a portion of his overall direct ownership stake.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kirn David
(Last)(First)(Middle)
C/O 4D MOLECULAR THERAPEUTICS INC.
5858 HORTON STREET #455
(Street)
EMERYVILLE CALIFORNIA 94608
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026S(1)114,746D$10.4653(2)942,485D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
2. The transaction was executed in multiple trades in prices ranging from $10.00 to $10.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks:
President and Chief Executive Officer
/s/ Scott Bizily as Attorney-in-Fact for David Kirn06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR